1-9 of 9
Laia Paré
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial

Maria Vidal, Claudette Falato, Tomás Pascual, Rodrigo Sanchez-Bayona, Montserrat Muñoz-Mateu, Isaac Cebrecos, Xavier Gonzalez-Farré, Tomás Cortadellas, Mireia Margelí Vila, Miguel A. Luna, Christian Siso, Kepa Amillano, Patricia Galván, Milana A. Bergamino, Juan M. Ferrero-Cafiero, Fernando Salvador, Alejandra Espinosa Guerrero, Laia Pare, Esther Sanfeliu, Aleix Prat, Meritxell Bellet
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF10.
https://doi.org/10.1158/1078-0432.CCR-24-2460
Published: 18 February 2025
View article titled, Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial
Open the PDF for Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial in another window
Includes: Supplementary data
Journal Articles

HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial

Antonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany, Laia Paré, Guillermo Villacampa, Maria Gion, Peter Schmid, Marco Colleoni, Manuel R. Borrego, Patricia Galván, Joel S. Parker, Wesley Buckingham, Charles M. Perou, Patricia Villagrasa, Jose A. Guerrero, Miguel Sampayo-Cordero, Mario Mancino, Aleix Prat, Javier Cortés
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4123–4130.
https://doi.org/10.1158/1078-0432.CCR-24-0464
Published: 13 September 2024
View article titled, HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial
Open the PDF for HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial in another window
Includes: Supplementary data
Journal Articles

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, Aleix Prat, Matthias Christgen, Sherko Kuemmel, Mohammad Parsa Mohammadian, Daniel Gebauer, Ronald Kates, Laia Paré, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Rachel Wuerstlein, Monika Graeser, Enrico Pelz, Katarzyna Jóźwiak, Christine zu Eulenburg, Hans Heinrich Kreipe, Nadia Harbeck, on behalf of the ADAPT TN investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4995–5003.
https://doi.org/10.1158/1078-0432.CCR-22-0482
Published: 14 November 2022
View article titled, De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Open the PDF for De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial in another window
Includes: Supplementary data
Journal Articles

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy

Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarneri, Javier Cortes, Patricia Villagrasa, Núria Chic, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Gaia Griguolo, Antonio Llombart, Pierfranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Paré, Patricia Galvan, Lisa A. Carey, Charles M. Perou, Aleix Prat
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3116–3125.
https://doi.org/10.1158/1078-0432.CCR-20-4102
Published: 01 June 2021
View article titled, Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy
Open the PDF for Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy in another window
Includes: Supplementary data
Journal Articles

A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer

Aleix Prat, Yi-Hsuan Tsai, Tomás Pascual, Laia Paré, Barbara Adamo, Maria Vidal, Fara Brasó-Maristany, Patricia Galván, Jan Christoph Brase, Vanessa Rodrik-Outmezguine, Stephen Johnston, Eva Ciruelos, Joel S. Parker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6141–6148.
https://doi.org/10.1158/1078-0432.CCR-20-2793
Published: 01 December 2020
View article titled, A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
Open the PDF for A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype

Valentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni, Alba A. Brandes, Antonio Frassoldati, Luigi Cavanna, Antonino Musolino, Francesco Giotta, Anita Rimanti, Ornella Garrone, Elena Bertone, Katia Cagossi, Oriana Nanni, Federico Piacentini, Enrico Orvieto, Gaia Griguolo, Matteo Curtarello, Loredana Urso, Laia Paré, Nuria Chic, Roberto D'Amico, Aleix Prat, Pierfranco Conte
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (22): 5843–5851.
https://doi.org/10.1158/1078-0432.CCR-20-1731
Published: 13 November 2020
View article titled, <em>PIK3CA</em> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Open the PDF for <em>PIK3CA</em> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype in another window
Includes: Supplementary data
Journal Articles

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

Eva Ciruelos, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sonia Pernas, Laia Paré, Santiago Escrivá-de-Romaní, Luis Manso, Barbara Adamo, Eduardo Martínez, Javier Cortés, Silvia Vazquez, Antonia Perelló, Isabel Garau, Mireia Melé, Noelia Martínez, Alvaro Montaño, Begoña Bermejo, Serafin Morales, María J. Echarri, Estela Vega, Blanca González-Farré, Débora Martínez, Patricia Galván, Jordi Canes, Paolo Nuciforo, Xavier Gonzalez, Aleix Prat
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 5820–5829.
https://doi.org/10.1158/1078-0432.CCR-20-0844
Published: 13 November 2020
View article titled, Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
Open the PDF for Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial in another window
Includes: Supplementary data
Journal Articles

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

Aleix Prat, Ana Lluch, Arran K. Turnbull, Anita K. Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, José Ignacio Chacón, Pedro Sánchez-Rovira, Arrate Plazaola, Montserrat Muñoz, Laia Paré, Joel S. Parker, Nuria Ribelles, Begoña Jimenez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Barbara Adamo, Mitch Dowsett, Eva Carrasco, Miguel Martín, J. Michael Dixon, Charles M. Perou, Emilio Alba
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (12): 3035–3044.
https://doi.org/10.1158/1078-0432.CCR-16-2092
Published: 14 June 2017
View article titled, A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse
Open the PDF for A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse in another window
Includes: Supplementary data
Journal Articles

Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer

Rebeca Sanz-Pamplona, Adriana Lopez-Doriga, Laia Paré-Brunet, Kira Lázaro, Fernando Bellido, M. Henar Alonso, Susanna Aussó, Elisabet Guinó, Sergi Beltrán, Francesc Castro-Giner, Marta Gut, Xavier Sanjuan, Adria Closa, David Cordero, Francisco D. Morón-Duran, Antonio Soriano, Ramón Salazar, Laura Valle, Victor Moreno
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (20): 4709–4718.
https://doi.org/10.1158/1078-0432.CCR-15-0159
Published: 14 October 2015
View article titled, Exome Sequencing Reveals <em>AMER1</em> as a Frequently Mutated Gene in Colorectal Cancer
Open the PDF for Exome Sequencing Reveals <em>AMER1</em> as a Frequently Mutated Gene in Colorectal Cancer in another window
Includes: Supplementary data